All In Biotech

Drug Trial Radar · NCT03155191

Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia

A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia

Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Jun 1, 2017

Primary completion

Mar 31, 2035

Study completion Mar 31, 2035

Sponsor

Lead sponsor
Takara Bio Inc.Industry
Sponsor type
Industry
First posted
May 16, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.

Conditions

  • Lymphoblastic Leukemia, Acute Adult

Interventions

  • TBI-1501Biological

    Phase-I portion: Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg). Phase-II portion: Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase-I portion: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: One year
  2. Phase-II portion: Anti-tumor effect (CR+CRi rate)Time frame: 56 days

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Akita University Hospital

    Akita, Akita, Japan

  • University Of Fukui Hospital

    Yoshida, Fukui, Japan

  • Kyushu University Hospital

    Higashiku, Fukuoka, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Kobe City Medical Center General Hospital

    Kobe, Hyōgo, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Okayama University Hospital

    Okayama, Okayama-ken, Japan

  • Jichi Medical University hospital

    Shimotsuke-shi, Tochigi, Japan

  • Cancer Institute Hospital Of JFCR

    Kōto, Tokyo, Japan

  • The Institute of Medical Science, The University of Tokyo

    Minato-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.